News

The newly published research highlights N-acetyltaurine's (NAT) potential for significant weight loss through appetite suppression.

The licensing agreement is for two promising metabolites with the potential to significantly improve metabolic health and naturally address the obesity epidemic.

Stanford’s High Impact Technology (HIT) Fund is kicking off its third year of helping researchers commercialize their most promising ideas.

Study to Evaluate MTX-101 for Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Adults and Patients

This edition brings you our FY2023 Annual Report: "Lab to Life: Advancing Innovation"

SYNCAR-001 + STK-009 combination will be studied in two distinct lupus patient populations: non-renal systemic lupus erythematosus (SLE) and lupus nephritis (LN)

BridgeBio merged with Stanford Startup Eidos Therapeutics in 2021

They've entered into worldwide collaboration with Sanofi to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases.

Featured: InvinciKids & the Stanford Chariot Program deliver virtual reality alternatives for pediatric anesthesiology

Featured: Discussing the Promise and Future of RNA Medicines with Dr. Howard Chang

The High Impact Technology (HIT) Fund provides business guidance and industry connections to Stanford researchers and entrepreneurs, as well as awards of up to $250,000.

The collaboration will enable the development of medications to treat a type of brain cancer.

Stanford’s Carolyn Bertozzi wins Nobel in chemistry